基本信息
浏览量:15
职业迁徙
个人简介
Research Interests
The Rihe Liu group’s interests include
the systematic development of clinically amenable targeting ligands that tightly and highly specifically bind to biomarkers on the surface of cancer cells from protein domain libraries and nuclease-resistant nucleic acid libraries with unusually high diversity;
the identification of natural and synthetic proteins with desired biological functions and elucidation of the related protein-protein, enzyme-substrate, and drug-target interaction networks at a proteome-wide scale using combinatorial biochemistry and chemical biology approaches.
The group is particularly interested in developing novel cancer biomarker-binding theranostic molecules that are based on the single domain antibodies or their mimics with human origins using sophisticated protein display technologies. They are also developing cancer biomarker-binding affinity molecules that are based on the nuclease-resistant nucleic acid aptamers using a combination of conventional SELEX, cell-SELEX, and in vivo SELEX technology platforms. The resulting targeting ligands are further engineered to have desired multispecificity and avidity and applied in translational research using xenograft, orthotopic, and patient-derived animal models.
研究兴趣
论文共 91 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ying Wang,Sirui Li,Mengying Hu,Yuchen Yang, Ellie McCabe, Lillian Zhang, Andrew M. Withrow,Jenny P.-Y. Ting,Rihe Liu
Nature Nanotechnologyno. 6 (2024): 1-11
Chemical communications (Cambridge, England) (2023)
CHEMICAL COMMUNICATIONSno. 97 (2023): 14387-14390
Journal of controlled release : official journal of the Controlled Release Society (2023): 872-887
Molecular therapy : the journal of the American Society of Gene Therapyno. 1 (2022): 119-133
Journal of Controlled Release (2022): 303-313
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn